华东医药 (000963)

HUADONG MEDICINE CO.,LTD

ASZ

Tags

300ESG Index300 Non-Cyclical IndexMSCI Component StocksCSI 200 IndexGeneric DrugsInsurance Heavy PositionsImmunotherapyWeight Loss DrugsAnalyst Recommended StocksInnovative DrugsChemical PharmaceuticalsNorthbound Heavy PositionsMedical Aesthetics ConceptPharmaceuticals and HealthcareFace Mask ProtectionSynthetic BiologyEmerging Markets IndexPrivate Enterprises 100 IndexHigh-Performing StocksIndustry LeadersChina Securities Finance and Central Huijin HoldingsYangtze River DeltaNon-Cyclical StocksHigh Accounts ReceivableShenzhen Main Board 50 IndexShenzhen ConnectSZSE 100 IndexSZSE 300 IndexSZSE Governance IndexCSFC HoldingsPharma & BiotechSZSE Defensive 50 IndexStable Growth IndexSHS Technology Leaders IndexConsumer Services IndexSZSE Medicine Equal Weight IndexSZSE 100 Equal Weight IndexYangtze River Protection IndexCSI Emerging Industries IndexJuchao Large-cap IndexShenzhen A-Share Pharmaceutical IndexSHS Dividend Growth Low Volatility IndexBOC International CSI 300 ESG IndexCSI 300 Quality IndexCSI 100 Low Volatility IndexCSI All-share Pharmaceutical Sector IndexSZSE Emerging Industries IndexSZSE 1000 IndexHangzhou Bay Area IndexSZSE 300 Return IndexCSSW Health IndexSZSE Component Index ReturnCSI 300 Equal Weight IndexCSI 300 ESG IndexLarge & Mid-cap IndexShanghai-Hong Kong-Shenzhen 300 IndexCNI 1000 IndexXingyin Wealth Management Balanced 300 IndexCSSW Silk Road IndexPhoenix 50 IndexOrient Securities Value IndexMilitary PartsMSCIYangtze River Delta Economic ZoneFTSE Russell ConceptLarge-cap Blue-chipInsurance Heavy HoldingsMedical AestheticsWholesale & Retail IndexCSI 300 Non-cyclical IndexPension Industry IndexSZSE Selected IndexSZSE Responsibility IndexTechnology 50 Strategy IndexCS High-end Manufacturing IndexCSI 300 Shenzhen Market IndexSZSE 100 Return IndexSHS Innovative Drugs IndexTechnology Pioneer IndexSZSE ChiNext 100 IndexSecurities Times Value 100 IndexSZSE Pharmaceutical IndexCSI 800 IndexCS Pharmaceutical TI Index100 Performance IndexCSI 300 Preferred IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexCNI 300 IndexCCTV 500 IndexCSI 300 USD (CNH) IndexSZSE Private Enterprises IndexHua Xia Bank ESG IndexCS Pharmaceutical Innovation IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexSZSE Low Volatility IndexCSI All-share Pharmaceutical IndexCSI 300 USD IndexSZSE Pharmaceutical 50 IndexSZSE 300 Equal Weight IndexZhaoyang 100 IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightPharmaceutical & Health 100 IndexInnovative Drugs 30 IndexCSI 300 Value Stable IndexCSI 300 Pharmaceutical IndexCSI 700 IndexAH Economic Blue-chip IndexSZSE Fundamental 200 IndexPharmaceutical 50 IndexPharmaceutical 50 Strategy IndexYangtze River 100 IndexCS Innovative Drugs IndexESG 300 IndexZhejiang 100 IndexChina Economic Index GDPCSI 1000 Value IndexSZSE Fundamental 120 IndexFundamental 600 IndexCS Yangtze River Delta IndexStrategic Emerging Industries 100 IndexZhejiang

K-Line Chart

No K-line data available

Company NameEast China Pharmaceutical Co., Ltd.
Listing Date2000-01-27
Issue Price5.76RMB
Registered Capital175402.104810k RMB
Legal RepresentativeLv Liang
Registered Address47th Floor, No. 439 North Zhongshan Road, Gongshu District, Hangzhou City, Zhejiang Province
IndustryChemical Pharmaceuticals
Main BusinessIntegrating pharmaceutical R&D, manufacturing and sales, drug distribution and retail, modern pharmaceutical logistics, health industry, and medical aesthetic product manufacturing and sales.
Company ProfileEast China Pharmaceutical Co., Ltd. was founded in 1993. It is primarily engaged in the production and sales of antibiotics, traditional Chinese patent medicines, chemical synthetic drugs, and genetic engineering drugs, as well as the wholesale and retail distribution of Chinese and Western medicines, Chinese medicinal herbs, medical devices, etc. It is a large comprehensive listed pharmaceutical company integrating pharmaceutical R&D, pharmaceutical manufacturing, drug distribution, retail, and pharmaceutical logistics, undertaking national, provincial, and municipal government special drug reserve tasks. The company successfully issued 50 million A-shares on the Shenzhen Stock Exchange in December 1999 (Stock Abbreviation: East China Pharmaceutical, Stock Code: 000963).

Stock Details

1. Key Indicators

  • Total Shares(W): 175402.10
  • Circulating A-Shares(W): 175337.54
  • Earnings Per Share(RMB): 1.5682
  • Net Assets Per Share(RMB): 13.7586
  • Operating Revenue(W RMB): 3266414.31
  • Total Profit(W RMB): 326262.16
  • Net Profit Attributable to Parent(W RMB): 274791.60
  • Net Profit Growth Rate(%): 7.24
  • Weighted Return on Equity(%): 11.3900
  • Operating Cash Flow Per Share(RMB): 1.4890
  • Undistributed Profit Per Share(RMB): 10.5891
  • Capital Reserve Per Share(RMB): 1.3784

2. Main Business

The main business covers:

  • Pharmaceutical Industry
  • Pharmaceutical Commerce
  • Medical Aesthetics
  • Industrial Microbiology

3. Company Basic Information

  • Company Name: Huadong Medicine Co., Ltd.
  • Listing Date: 2000-01-27
  • Industry: Medicine & Healthcare - Chemical Pharmaceuticals
  • Address: 858 Moganshan Road, Gongshu District, Hangzhou City, Zhejiang Province
  • Website: www.eastchinapharm.com
  • Company Profile: The predecessor of the company, Hangzhou Pharmaceutical Station Co., Ltd., was established in March 1993 by way of private placement, with Hangzhou Pharmaceutical Purchasing and Supply Station as the main sponsor, jointly initiated by Hangzhou Minsheng Pharmaceutical Factory and Zhejiang Xinchang Pharmaceutical Co., Ltd. Hangzhou Pharmaceutical Purchasing and Supply Station was established in 1958 as a state-owned enterprise under the Hangzhou Pharmaceutical Administration Bureau. It was the largest pharmaceutical wholesale enterprise in Zhejiang Province, mainly engaged in six major categories of pharmaceutical products: drugs, Chinese medicinal materials, Chinese patent medicines, medical devices, chemical reagents, and glass instruments. It was promoted to a national second-class enterprise in 1990 and was a provincial and municipal credit excellent enterprise. In 1995, Hangzhou Huadong Pharmaceutical (Group) Company and Hangzhou Pharmaceutical Station Co., Ltd. carried out a joint reorganization. In October 1996, the Hangzhou State-owned Assets Bureau approved with document Hang Guozi [96] No. 183, authorizing Hangzhou Huadong Pharmaceutical (Group) Company to hold all the state shares of Hangzhou Pharmaceutical Station Co., Ltd. In November 1996, Hangzhou Pharmaceutical Station Co., Ltd. carried out a rights issue and changed its name after cleaning up and standardizing its original share capital structure. On January 17, 1997, the company completed the industrial and commercial change registration and was renamed Hangzhou Huadong Pharmaceutical Co., Ltd., with the total share capital increased to 140 million shares. Since then, the company has transformed from a purely commercial enterprise into a pharmaceutical production enterprise that integrates pharmaceutical product production and sales networks, closely combining industry and commerce.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 China Yuanda Group Co., Ltd. General Legal Person 73093.82 41.72
2 Hangzhou Huadong Pharmaceutical Group Co., Ltd. General Legal Person 28800.00 16.44
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 5200.36 2.97
4 China Securities Finance Corporation Ltd. Special Legal Person 2218.68 1.27
5 China Europe Healthcare Hybrid Securities Investment Fund Class A Fund 2011.52 1.15
6 New China Life Insurance Co., Ltd. - Dividend - Individual Dividend - 018L-FH002 Shen Insurance 1979.20 1.13
7 National Social Security Fund 112 Portfolio Social Security Fund 1698.97 0.97
8 New China Life Insurance Co., Ltd. - Traditional - Ordinary Insurance Product - 018L-CT001 Shen Insurance 1559.71 0.89
9 Huatai-PineBridge CSI 300 ETF Fund 1488.22 0.85
10 E Fund CSI 300 Healthcare ETF Fund 1098.64 0.63

5. Concept Sectors

  • Immunotherapy
  • Artificial Intelligence
  • Generic Drugs
  • Mask Protection
  • Medical Aesthetics Concept
  • Cold Chain Logistics
  • Hepatitis Concept
  • Innovative Drugs
  • Weight Loss Drugs
  • Synthetic Biology
  • Pet Economy
  • AI Healthcare
  • Margin Trading
  • Insurance Heavy Holdings
  • Blue Chip Stocks
  • Social Security Fund Heavy Holdings
  • Industry Leader
  • China Securities Finance & Central Huijin
  • MSCI Constituent
  • Northbound Heavy Holdings
  • Non-Cyclical Stocks
  • High Accounts Receivable
  • SZSE 100
  • SZSE 300
  • SZSE Governance
  • Consumption 100
  • Private Enterprise 100
  • CSI 300
  • CSI 200
  • 300 Non-Cyclical
  • SZSE Innovation
  • 300 ESG
  • Emerging Composite Index
  • Yangtze River Delta
  • SZSE Main Board 50
  • Analyst Index

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information